NASDAQ:GOVX GeoVax Labs (GOVX) Stock Price, News & Analysis $0.77 +0.02 (+2.69%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GeoVax Labs Stock (NASDAQ:GOVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GeoVax Labs alerts:Sign Up Key Stats Today's Range$0.74▼$0.7950-Day Range$0.48▼$1.3252-Week Range$0.43▼$8.28Volume867,261 shsAverage Volume1.01 million shsMarket Capitalization$12.26 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingBuy Company Overview GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia. Read More GeoVax Labs Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreGOVX MarketRank™: GeoVax Labs scored higher than 37% of companies evaluated by MarketBeat, and ranked 734th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGeoVax Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGeoVax Labs has only been the subject of 1 research reports in the past 90 days.Read more about GeoVax Labs' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GeoVax Labs are expected to grow in the coming year, from ($4.49) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeoVax Labs is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeoVax Labs is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeoVax Labs has a P/B Ratio of 4.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GeoVax Labs' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.71% of the float of GeoVax Labs has been sold short.Short Interest Ratio / Days to CoverGeoVax Labs has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeoVax Labs has recently increased by 51.01%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeoVax Labs does not currently pay a dividend.Dividend GrowthGeoVax Labs does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted23.71% of the float of GeoVax Labs has been sold short.Short Interest Ratio / Days to CoverGeoVax Labs has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeoVax Labs has recently increased by 51.01%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.59 News SentimentGeoVax Labs has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for GeoVax Labs this week, compared to 1 article on an average week.Search InterestOnly 17 people have searched for GOVX on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added GeoVax Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GeoVax Labs insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of GeoVax Labs is held by insiders.Percentage Held by InstitutionsOnly 6.09% of the stock of GeoVax Labs is held by institutions.Read more about GeoVax Labs' insider trading history. Receive GOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address GOVX Stock News HeadlinesGeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine ConstructsAugust 20 at 8:48 PM | theglobeandmail.comGeoVax to Present at the Emerging Growth Conference on August 20, 2025August 20 at 10:46 AM | finance.yahoo.comThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”August 23 at 2:00 AM | Weiss Ratings (Ad)GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency DesignationJuly 29, 2025 | finance.yahoo.comGeoVax Labs, Inc. (GOVX) Q2 2025 Earnings Call TranscriptJuly 28, 2025 | seekingalpha.comGeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox VaccineJuly 21, 2025 | finance.yahoo.comGeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks ExpandJuly 16, 2025 | finance.yahoo.comGeoVax Labs, Inc. (GOVX) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comSee More Headlines GOVX Stock Analysis - Frequently Asked Questions How have GOVX shares performed this year? GeoVax Labs' stock was trading at $2.47 at the beginning of 2025. Since then, GOVX shares have decreased by 68.8% and is now trading at $0.77. How were GeoVax Labs' earnings last quarter? GeoVax Labs Inc. (NASDAQ:GOVX) released its quarterly earnings data on Monday, July, 28th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.06. The firm had revenue of $0.85 million for the quarter, compared to the consensus estimate of $0.37 million. GeoVax Labs had a negative trailing twelve-month return on equity of 408.80% and a negative net margin of 403.88%. Read the conference call transcript. When did GeoVax Labs' stock split? GeoVax Labs's stock reverse split on Wednesday, January 31st 2024.The 1-15 reverse split was announced on Wednesday, January 31st 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of GeoVax Labs? Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GeoVax Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeoVax Labs investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), KALA BIO (KALA), Lipocine (LPCN), Fortress Biotech (FBIO) and Ovid Therapeutics (OVID). Company Calendar Last Earnings7/28/2025Today8/23/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GOVX CIK832489 Webwww.geovax.com Phone(678) 384-7220Fax678-384-7281Employees10Year FoundedN/APrice Target and Rating Average Price Target for GeoVax Labs$8.50 High Price Target$9.00 Low Price Target$8.00 Potential Upside/Downside+1,003.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.99 million Net Margins-403.88% Pretax Margin-403.88% Return on Equity-408.80% Return on Assets-279.89% Debt Debt-to-Equity RatioN/A Current Ratio2.03 Quick Ratio2.03 Sales & Book Value Annual Sales$6.14 million Price / Sales2.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book4.28Miscellaneous Outstanding Shares15,925,000Free Float15,734,000Market Cap$12.26 million OptionableNot Optionable Beta3.27 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:GOVX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeoVax Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.